Dexmedetomidine reduces acute kidney injury in high-risk but not low-risk patients after non-cardiac surgery: secondary analysis of a randomized controlled trial.
Xin-Quan Liang, Mei-Lin Li, Chun-Jing Li
✦ AI-curated · Sources linked
In 30 seconds
This secondary analysis of a randomized, double-blind, placebo-controlled trial assessed intraoperative dexmedetomidine and acute kidney injury (AKI) in patients aged 60 years or older undergoing elective non-cardiac surgery. Risk was classified using the General Surgery Acute Kidney Injury Risk Index, and AKI was assessed within 7 postoperative days. Among high-risk patients, AKI occurred in 12.6% (13/103) with dexmedetomidine versus 23.4% (25/107) with placebo (RR 0.54, 95% CI 0.29 to 1.00, P = 0.043). Low-risk patients had no significant difference between groups.
Key findings
- In high-risk patients, dexmedetomidine was associated with lower AKI incidence: 12.6% (13/103) versus 23.4% (25/107); RR 0.54, 95% CI 0.29 to 1.00, P = 0.043.
- After multivariable adjustment, dexmedetomidine remained associated with lower AKI risk in high-risk patients (OR 0.44, 95% CI 0.20 to 0.98, P = 0.045).
- Among low-risk patients, AKI incidence did not differ significantly: 7.9% versus 9.6%; RR 0.82, 95% CI 0.44 to 1.55, P = 0.543.
- Urological surgery was an independent predictor of AKI across the cohort.
Why it matters
Postoperative AKI is associated with poor long-term outcomes, and these findings suggest that any kidney-protective association of intraoperative dexmedetomidine may differ by baseline AKI risk. The risk-stratified results are relevant when interpreting perioperative evidence, while the absence of a significant difference in low-risk patients cautions against assuming a uniform effect across surgical patients.
What to keep in mind
This was a secondary analysis of a randomized trial, and the reported benefit was confined to the high-risk subgroup; the abstract does not report whether the subgroup comparison was prespecified.